Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma

Trial Profile

Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Pralatrexate (Primary) ; Romidepsin (Primary)
  • Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 According to results published in the Blood, as of march 1st 2017, 29 patients were enrolled on the phase 1 study.
    • 15 Nov 2017 Results (n=29) of phase1 assessing safety, tolerability and early activity of response for the combination of pralatrexate and romidepsin, were published in the Blood.
    • 19 Jun 2017 According to a Spectrum Pharmaceuticals media release, results from the phase I study have been presented at the 14th International Conference on Malignant Lymphoma (ICML) meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top